Bruker Daltonics Announces Selection for Phase II of the ARFCAM R&D Project by the Department of Homeland Security

Bruker Daltonics NBC Detection Corporation today
announces that it has received a $0.75 million follow-on Phase II
contract award for further research and development into the
Autonomous Rapid Facility Chemical Agent Monitor (ARFCAM) from the
U.S. Department of Homeland Security. ARFCAM is intended to be the
next generation chemical agent monitor for government facilities.
   Frank Thibodeau, Vice President for NBC Business Development,
commented: "This award indicates that Bruker Daltonics has performed
well in Phase I and has unique expertise to design and deliver the
next-generation technology to help protect our country from the threat
of chemical terrorism. This is a challenging program with accelerated
timelines and ambitious technical specifications, and we are gratified
that the Department of Homeland Security has shown confidence in the
ability of Bruker Daltonics to meet these requirements."

   ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

   Bruker BioSciences, headquartered in Billerica, Massachusetts, is
the publicly traded parent company of Bruker Daltonics Inc. and Bruker
AXS Inc. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry, as well as a
developer and provider of nuclear, biological and chemical (NBC)
detection systems. Bruker AXS is a leading developer and provider of
life science and advanced materials research tools based on X-ray
technology. For more information about Bruker BioSciences Corporation,
please visit www.bruker-biosciences.com

   CAUTIONARY STATEMENT

   Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements as
that term is defined in the Private Securities Litigation Reform Act
of 1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results to
differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the companies'
reorganization strategies, integration risks, failure of conditions,
technological approaches, product development, market acceptance, cost
and pricing of the companies' products, changes in governmental
regulations, capital spending and government funding policies, FDA and
other regulatory approvals to the extent applicable, competition, the
intellectual property of others, patent protection and litigation.
These and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our
respective annual reports on Form 10-K for the year ended December 31,
2004, our most recent quarterly reports on Form 10-Q, our current
reports on Form 8-K and the joint proxy statement/prospectus filed in
connection with the merger. We disclaim any intent or obligation to
update these forward-looking statements.